Denali Therapeutics Inc. (DNLI) Social Stream
Denali Therapeutics Inc (DNLI) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Denali Therapeutics Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 11 | $105 | $60 | $84.4 | $32.17 | 162.36% |
| 2021-11-17 | 11 | $105 | $60 | $84.3 | $32.17 | 162.05% |
| 2021-12-22 | 11 | $105 | $60 | $81.3 | $32.17 | 152.72% |
| 2022-01-13 | 11 | $105 | $60 | $80.5 | $32.17 | 150.23% |
| 2022-01-20 | 10 | $105 | $60 | $78.5 | $32.17 | 144.02% |
| 2022-02-10 | 10 | $105 | $60 | $76.1 | $32.17 | 136.56% |
| 2022-03-01 | 10 | $105 | $60 | $76.1 | $32.17 | 136.56% |
| 2022-03-07 | 11 | $105 | $41 | $73.2 | $32.17 | 127.54% |
The Trend in the Analyst Price Target
Over the past 14 months, DNLI's average price target has gone up $9.6.
DNLI reports an average of 74.42% for its upside potential over the past 48 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-04-10 | 6 | 106 | 18 | 81.00 | 52.26 | 54.99% |
| 2021-05-08 | 11 | 106 | 18 | 79.11 | 54.30 | 45.69% |
| 2021-12-22 | 11 | 105 | 60 | 81.30 | 46.78 | 73.79% |
| 2022-01-13 | 11 | 105 | 60 | 80.50 | 33.86 | 137.74% |
| 2022-03-01 | 10 | 105 | 60 | 76.10 | 32.10 | 137.07% |
DNLI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.41 | 8 | 1 | 2 | 0 | 0 | 11 |
The Trend in the Broker Recommendations
Over the past 90 days, DNLI's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- Denali Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 831.58% of all US stocks.
- In terms of how Denali Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is higher than 821.52% of that group.
- Denali Therapeutics Inc's average analyst price target is higher than 820.31% of Pharmaceutical Products stocks.
- Denali Therapeutics Inc's variance in analysts' estimates is lower than -646.25% of stocks in the large market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Denali Therapeutics Inc are DNA, CRSP, and BNTX.
Make investment decisions regarding DNLI using the data that counts. Try POWR Ratings for free.